U46619 is a stable synthetic
analog of the endoperoxide
prostaglandin PGH2 first prepared in 1975,[1] and acts as a thromboxane A2 (TP) receptor agonist. It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations and exhibits many properties similar to thromboxane A2, including shape change and aggregation of platelets [2] and smooth muscle contraction. U46619 is a
vasoconstrictor that mimics the hydroosmotic effect of
vasopressin.[3]
References
^Bundy, G. L. (1975). "Synthesis of prostaglandin endoperoxide analogs". Tetrahedron Letters. 16 (24): 1957–1960.
doi:
10.1016/S0040-4039(00)72333-1.
^Liel, N.; Mais, D.E.; Halushka, P.V (1987). "Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets". Prostaglandins. 33 (6): 789–797.
doi:
10.1016/0090-6980(87)90107-9.
PMID2959986.
^Burch, Ronald M.; Halushka, Perry V. (1983). "Calcium-45 fluxes in isolated toad bladder epithelial cells: effects of agents which alter water or sodium transport". Journal of Pharmacology and Experimental Therapeutics. 224 (1): 108–17.
PMID6294273.